Ariel Feldstein, M.D.


Gastroenterology, Hepatology and Nutrition


3020 Children's Way
MC 5030
San Diego, CA 92123


Gastroenterology, Hepatology and Nutrition


Rady Children's Specialists of San Diego

Medical Group / IPA

Rady Children's Specialists

Medical School

Universidad de Buenos Aires


Mayo Clinic


Mayo Clinic

Board Certifications

Pediatric Gastroenterology, Pediatrics


Dr. Ariel Feldstein is chief of the Gastroenterology, Hepatology & Nutrition Division at Rady Children's Hospital-San Diego and a professor of pediatrics at UC San Diego School of Medicine.

After graduating from the Universidad de Buenos Aires Medical School and completing a postdoctoratal program in physiology at the Mayo Clinic, Dr. Feldstein went on to become the director of research for the Pediatric Institute at the Cleveland Clinic before moving to San Diego in 2011.

Dr. Feldstein oversees one of the largest pediatric gastroenterology divisions in the country, which is a top-ranked program by US News & World Report. He is a renowned pediatric hepatologist who pioneered the development of non-invasive blood tests to monitor liver damage. His research is supported by several grants from the National Institutes of Health, professional associations such as the American College of Gastroenterology and pharmaceutical industry leaders. He and his lab have made significant contributions to understanding and developing therapies for obesity-associated liver disease, now the most common form of chronic liver disease in children.

Dr. Feldstein has published over 120 peer-reviewed publications in various medical journals. He currently serves as the associate editor of Seminars for Liver Disease and has held editorial positions on other gastroenterology and hepatology journals. He is a member of the Society for Pediatric Research and numerous specialty societies and has held leadership roles in the American Gastroenterological Association and the American Association for the Study of Liver Diseases.

His goal is to use his research to develop safe and effective diagnostic and therapeutic strategies for patients with highly prevalent and potentially serious conditions.


Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center.
Kathemann S, Bechmann LP, Sowa JP, Manka P, Dechêne A, Gerner P, Lainka E, Hoyer PF, Feldstein AE, Canbay A

Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort.
Pan JJ, Fisher-Hoch SP, Chen C, Feldstein AE, McCormick JB, Rahbar MH, Beretta L, Fallon MB

Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis.
Eguchi A, Yoshitomi T, Lazic M, Johnson CD, Vong LB, Wree A, Povero D, Papouchado BG, Nagasaki Y, Feldstein AE

Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD.
Nagpal SJ, Lopez R, Feldstein AE, Alkhouri N

Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.
Wree A, Johnson CD, Font-Burgada J, Eguchi A, Povero D, Karin M, Feldstein AE

Microparticles release by adipocytes act as "find-me" signals to promote macrophage migration.
Eguchi A, Mulya A, Lazic M, Radhakrishnan D, Berk MP, Povero D, Gornicka A, Feldstein AE

Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis.
Alkhouri N, Alisi A, Okwu V, Matloob A, Ferrari F, Crudele A, De Vito R, Lopez R, Feldstein AE, Nobili V

Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Pizarro M, Solís N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M

Circulating microRNAs: emerging biomarkers of liver disease.
Arrese M, Eguchi A, Feldstein AE

Endoscopic treatment of pediatric post-transplant biliary complications is safe and effective.
Dechêne A, Kodde C, Kathemann S, Treckmann J, Lainka E, Paul A, Gerken G, Feldstein AE, Hoyer PF, Canbay A

The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE, Alkhouri N

Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.
Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE

Transient receptor potential vanilloid 1 gene deficiency ameliorates hepatic injury in a mouse model of chronic binge alcohol-induced alcoholic liver disease.
Liu H, Beier JI, Arteel GE, Ramsden CE, Feldstein AE, McClain CJ, Kirpich IA

Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients.
Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, Köfeler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A

Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis.
Lazic M, Inzaugarat ME, Povero D, Zhao IC, Chen M, Nalbandian M, Miller YI, Cherñavsky AC, Feldstein AE, Sears DD

Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis.
Navarro LA, Wree A, Povero D, Berk MP, Eguchi A, Ghosh S, Papouchado BG, Erzurum SC, Feldstein AE

Adipocyte cell death, fatty liver disease and associated metabolic disorders.
Eguchi A, Feldstein AE

Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice.
Aytekin M, Tonelli AR, Farver CF, Feldstein AE, Dweik RA

NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
Wree A, McGeough MD, Peña CA, Schlattjan M, Li H, Inzaugarat ME, Messer K, Canbay A, Hoffman HM, Feldstein AE

Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model.
Thapaliya S, Wree A, Povero D, Inzaugarat ME, Berk M, Dixon L, Papouchado BG, Feldstein AE

Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study.
Navaneethan U, Gutierrez NG, Venkatesh PG, Jegadeesan R, Zhang R, Jang S, Sanaka MR, Vargo JJ, Parsi MA, Feldstein AE, Stevens T

Letter: gender-associated cell-free microRNA profiles in non-alcoholic fatty liver disease--authors' reply.
Newton KP, Awai HI, Feldstein AE, Schwimmer JB

Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice.
Lazic M, Eguchi A, Berk MP, Povero D, Papouchado B, Mulya A, Johnson CD, Feldstein AE

OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease.
Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R, McIntyre TM, Feldstein AE, Hazen SL

Biomarkers of liver cell death.
Eguchi A, Wree A, Feldstein AE

See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.

PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.